Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDEA: Dupixent in Asthma with IL-4RαR576 Variant
NCT03694158Phase 4Active, not recruiting
- Sponsor
- Boston Children's Hospital
- Start
- Sep 2021
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dupilumab in asthma, sponsored by Boston Children's Hospital. Primary endpoint: Rate of asthma exacerbations at 48 weeks. Started Sep 2021; status: active, not recruiting.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03694158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03694158.